David Mulholland, MD
Cardiovascular Disease · Jackson, MSNPI 1578509501
Payments from drug & device makers
Across 626 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Novartis$1K
- Boehringer Ingelheim$990
- Merck$924
- Amgen$879
- AstraZeneca$651
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 109 | $1,749 |
| Novartis | 87 | $1,439 |
| Boehringer Ingelheim | 59 | $990 |
| Merck | 46 | $924 |
| Amgen | 64 | $879 |
| AstraZeneca | 31 | $651 |
| Boston Scientific | 35 | $493 |
| Esperion Therapeutics, Inc. | 27 | $467 |
| E.r. Squibb & Sons, L.L.C. | 23 | $396 |
| Pfizer | 23 | $390 |
| Scpharmaceuticals Inc. | 21 | $357 |
| Novo Nordisk | 15 | $286 |
| Alnylam Pharmaceuticals Inc. | 13 | $215 |
| Lexicon Pharmaceuticals, Inc. | 10 | $182 |
| Bayer | 8 | $171 |
| Chiesi USA, Inc. | 9 | $147 |
| Bridgebio Pharma, Inc. | 5 | $112 |
| Kowa Pharmaceuticals America, Inc. | 7 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Abbott | 2 | $49 |
| Abiomed | 2 | $48 |
| Atricure, Inc. | 2 | $46 |
| Medtronic | 1 | $44 |
| Cvrx, Inc. | 2 | $40 |
| Philips North America LLC | 2 | $37 |
| Gilead | 3 | $36 |
| GSK | 1 | $26 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
How this compares
$10,575 in reported general payments places this provider in the 70th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Jackson
- James HaysJackson$782K
- Donny StokesJackson$277K
- James HaysJackson$65K
- James BenslerJackson$64K
- Michael HallJackson$54K
- James WarnockJackson$48K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Kenneth MonahanJackson$31K
- Varun SardarJackson$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.